Regeneron Reports Third Quarter 2021 Financial and Operating Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- L3Harris CEO steps down amid conduct review, shares drop
- Reddit leads social media platforms in revenue growth per user
- Piper Sandler Starts SoFi Technologies (SOFI) at Overweight
- Northland Upgrades Astera Labs (ALAB) to Outperform, 'Right Time, Customers, and Products'
- Six dead in 'stampede-like' incident at India temple, ANI says
Regeneron's (REGN) Antibody Cocktail Can Prevent Covid-19 Infection for 8 Months, Phase 3 Data Shows
November 8, 2021 8:30 AM ESTShares of Regeneron Pharmaceuticals (NASDAQ: REGN) are up 1.5% in pre-open Monday after the company announced new phase 3 trial results for its antibody cocktail against COVID-19 infections.
Data showed that risks of getting COVID-19 were slashed by 82% for up to eight months in patients that... More
Regeneron (REGN) Tops Q3 EPS by $6.15
November 4, 2021 6:37 AM EDTRegeneron (NASDAQ: REGN) reported Q3 EPS of $15.37, $6.15 better than the analyst estimate of $9.22. Revenue for the quarter came in at $3.45 billion versus the consensus estimate of $2.76 billion.
For earnings history and earnings-related data on Regeneron (REGN) click here.
... More